MLYS

Mineralys Therapeutics' stock decreased by 18.6% in the first half of 2026, but showed a significant increase of 102.49% compared to the previous year. Key events included the release of Q1 2026 financial results, the FDA's acceptance of the NDA for lorundrostat, and the exploratory Phase 2 OSA trial results. Insider trading activity showed net buying, although some insiders executed pre-arranged sales. TD Cowen initiated coverage with a "Buy" rating, and the company has a consensus rating of "Moderate Buy" from analysts.